Department of Pharmacy, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China.
Department of Pharmacy, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China.
J Integr Med. 2021 Nov;19(6):469-477. doi: 10.1016/j.joim.2021.08.004. Epub 2021 Aug 25.
Hepatocellular carcinoma (HCC) is one of the most prevalent malignant cancers worldwide. Epithelial-mesenchymal transition (EMT), which endows epithelial cells with mesenchymal properties, plays an important role in the early stages of metastasis. Conventional cancer therapies have promising effects, but issues remain, such as high rates of metastasis and drug resistance. Thus, exploring and evaluating new therapies is an urgent need. Traditional Chinese medicines (TCMs) have been acknowledged for their multi-target and coordinated intervention effects against HCC. Accumulating evidence indicates that TCM can inhibit the malignancy of cells and the progression of EMT in HCC. However, studies on the effects of TCM on EMT in HCC are scarce. In this review, we summarized recent developments in anti-EMT TCMs and formulae, focusing on their underlying pharmacological mechanisms, to provide a foundation for further research on the exact mechanisms through which TCM affects EMT in HCC.
肝细胞癌 (HCC) 是全球最常见的恶性肿瘤之一。上皮-间充质转化 (EMT) 赋予上皮细胞间充质特性，在转移的早期阶段发挥重要作用。传统的癌症治疗方法具有很好的效果，但仍存在一些问题，如转移率高和耐药性。因此，探索和评估新的治疗方法是当务之急。中药 (TCM) 因其对 HCC 的多靶点和协同干预作用而得到认可。越来越多的证据表明，TCM 可以抑制 HCC 细胞的恶性转化和 EMT 的进展。然而，关于 TCM 对 HCC 中 EMT 的影响的研究还很少。在这篇综述中，我们总结了抗 EMT TCM 和配方的最新进展，重点介绍了它们的潜在药理学机制，为进一步研究 TCM 通过何种确切机制影响 HCC 中的 EMT 提供了基础。
